â»ê¿ä¾çº´¿ø
â¿ø»ï¼º¿ä¾çº´¿ø evening -keep, e-d °¡´É °£È£»ç ¸ðÁýÇÕ´Ï´Ù.
°æ»ó | ¹«°ü | ä¿ë½Ã
¿¡¹öºê·¹ÀÎÄÁ¼³ÆÃ(ÁÖ)
[´ëÇüÁ¦¾à»ç]ÀÇ»çmd(°æ·Â¹«°ü)/¾àÇйڻçor¾à»ç¸éÇã(Á¦¾à»ç°æ·Â)
¼¿ï | °æ·Â | ä¿ë½Ã
¿¡¹öºê·¹ÀÎÄÁ¼³ÆÃ(ÁÖ)
[´ëÇüÁ¦¾à»ç]ÀÇ»çmd(Á¦¾à»ç°æ·ÂÀº¿ì´ë)/ hematology, oncology µî Èñ±ÍÁúȯºÐ¾ß
¼¿ï | °æ·Â | ä¿ë½Ã
Çã±×¸¾Çã±×ÀÎ ½É¸®»ó´ã¼¾ÅÍ Ãµ¾ÈÁ¡
Çã±×¸¾Çã±×ÀÎ ½É¸®»ó´ã¼¾ÅÍ Ãµ¾ÈÁ¡°ú ÇÔ²² ÇÏ½Ç ÀÓ»ó½É¸®»ç¸¦ ¸ðÁýÇÕ´Ï´Ù.
ÃæÃ» | °æ·Â | ä¿ë½Ã
¿ä¼ÁÀÇ¿ø
Ä¡°úÀ§»ý»ç ¶Ç´Â °£È£Á¶¹«»ç(°è¾àÁ÷) ÃʺùÇÕ´Ï´Ù
¼¿ï | ¹«°ü | ä¿ë½Ã
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ)
[±Û·Î¹ú Á¦¾à»ç] medical manager, non-alcoholic steatohepatitis ä¿ë
¼¿ï | °æ·Â | ä¿ë½Ã
Â÷¿òÀÇ¿ø
[Â÷º´¿ø Â÷¿ò] ÇǺμºÇüŬ¸®´Ð ÇǺΰü¸®»ç ä¿ë
¼¿ï | °æ·Â | ³»Àϸ¶°¨
(D-1)
ÇǾؾ¾(P&C)
¼ö¼ú½Ç ¸¶Ãë°ú ¼±»ý´Ô Ãʺù
°æ±â | ¹«°ü | ä¿ë½Ã
ÇǾؾ¾(P&C)
¿µ»óÀÇÇаú Àü¹®ÀÇ Ãʺù
°æ³² | ¹«°ü | ä¿ë½Ã
È«Á¦¿¬¼¼Ä¡°úÀÇ¿ø
Áø·á½Ç Á÷¿ø ±¸ÇÕ´Ï´Ù~
¼¿ï | ¹«°ü | ä¿ë½Ã
¼º³ëº¹ÁöÀÇ·áÀç´Ü È¿ÀÚ¿ä¾çº´¿ø
È¿ÀÚ¿ä¾çº´¿ø¿¡¼ Áø·á¿øÀå´ÔÀ» ¸ð½Ê´Ï´Ù.
ÀüºÏ | ¹«°ü | ä¿ë½Ã
ÆË¼ºÇü¿Ü°úÀÇ¿ø
[¾Ð±¸Á¤¿ª] ÆË¼ºÇü¿Ü°úÀÇ¿ø¿¡¼ ¿øÀå´ÔÀ» ¸ð½Ê´Ï´Ù.
¼¿ï | ¹«°ü | ä¿ë½Ã
¿¡ÀÌÄ¡¾ËÄÁ¼³ÆÃ
Á¦¾à¹ÙÀÌ¿À(cra, pm,crm,com,ÀÓ»ó°³¹ß/Àü·«)
¼¿ï | °æ·Â | ä¿ë½Ã
¿¡¹öºê·¹ÀÎÄÁ¼³ÆÃ(ÁÖ)
[´ëÇüÁ¦¾à»ç] ÀÇ»çor¾à»ç¸éÇãor¾àÇйڻç/´ç´¢/°íÇ÷¾Ð/°ñ´Ù°øÁõ/ºñ´¢±âÁúȯ/cns
¼¿ï | °æ·Â | ä¿ë½Ã
¿¡¹öºê·¹ÀÎÄÁ¼³ÆÃ(ÁÖ)
[´ëÇüÁ¦¾à»ç] ±¹³» ÀÇ»ç ¸éÇã Çʼö/ hematology, oncology µî Èñ±ÍÁúȯºÐ¾ß
¼¿ï | °æ·Â | ä¿ë½Ã
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ)
[±Û·Î¹ú Á¦¾à»ç] study start-up associate °æ·ÂÁ÷ (Á¤±ÔÁ÷) ä¿ë
¼¿ï | °æ·Â | ä¿ë½Ã
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ)
[±Û·Î¹ú Á¦¾à»ç] clinical trial administrator ä¿ë
¼¿ï | °æ·Â | ä¿ë½Ã
Çб³¹ýÀÎ °¡Å縯ÇпøÀÇÁ¤ºÎ¼º¸ðº´¿ø
°¡Å縯´ëÇб³ ÀÇÁ¤ºÎ¼º¸ðº´¿ø °£È£ºÎ ÀÇ·áÁö¿øÁ÷(°è¾àÁ÷) »ó½Ã¸ðÁý
°æ±â | ½ÅÀÔ | ä¿ë½Ã
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ)
[±Û·Î¹ú Á¦¾à»ç]pharmacovigilance associate managerä¿ë
¼¿ï | °æ·Â | ä¿ë½Ã
À²µ¿¹°ÀÇ·á¼¾ÅÍ
¾È³»µ¥½ºÅ©/¸®¼Á¼Ç ä¿ë
¼¿ï | °æ·Â | ä¿ë½Ã
¼¿ï °ºÏ±¸ ¼öÀ¯3µ¿ 177-23 (ÁÖ)ÄÄÅ×Å©ÄÁ¼³ÆÃ:À¯Á¾Çö
Á÷¾÷Á¤º¸Á¦°ø»ç¾÷½Å°í¹øÈ£ : ¼¿ïºÏºÎ Á¦ 2008-01È£
Copyright ¨Ï ¸ÞµðÄÃÀâ. All rights reserved.
¼¿ï °ºÏ±¸ ¼öÀ¯3µ¿ 177-23
(ÁÖ)ÄÄÅ×Å©ÄÁ¼³ÆÃ:À¯Á¾Çö
Á÷¾÷Á¤º¸Á¦°ø»ç¾÷½Å°í¹øÈ£
¼¿ïºÏºÎ Á¦ 2008-01È£
Copyright ¨Ï ¸ÞµðÄÃÀâ. All rights reserved.